Badanie skuteczności i bezpieczeństwa batoklimabu u dorosłych z przewlekłą zapalną polineuropatią demielinizacyjną (CIDP)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a condition that affects the nerves, leading to muscle weakness and sometimes numbness. This study is focused on evaluating a treatment called batoclimab, which is given as a solution for injection. The study aims to see how effective and safe batoclimab is for adults with active CIDP. Participants in the study will receive either batoclimab or a placebo, which looks the same but has no active substance.

The purpose of the study is to compare batoclimab with the placebo to see if it helps maintain the clinical response in people who are already receiving treatments like immune globulin or plasma exchange for CIDP. The study will involve multiple centers and will be conducted in a way that neither the participants nor the researchers know who is receiving batoclimab or the placebo, ensuring unbiased results.

Participants will be monitored over a period to assess their response to the treatment. The study will measure various outcomes, such as the time it takes for symptoms to return and changes in muscle strength and disability scores. The goal is to determine if batoclimab can help keep the symptoms of CIDP under control more effectively than the placebo.